ISIN | LU1683287376 |
---|---|
Valor Number | 38312172 |
Bloomberg Global ID | |
Fund Name | UBS (Lux) Digital Health Equity Fund CB USD |
Fund Provider |
Credit Suisse Fund Management S.A.
Zürich, Switzerland Phone: +41 44 333 40 50 E-Mail: clientservices.amfunds@credit-suisse.com Web: www.credit-suisse.com |
Fund Provider | Credit Suisse Fund Management S.A. |
Representative in Switzerland |
UBS Fund Management (Switzerland) AG Basel Phone: +41 61 288 49 10 |
Distributor(s) |
UBS AG Basel Phone: +41 61 288 75 01 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel) |
Redemption Condition | The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel) |
Investment Strategy *** | The objective of the Subfund is to achieve the highest possible return in US dollars (Reference Currency), while taking due account of the principle of risk diversification, the security of the capital invested, and the liquidity of the assets. This Subfund aims to outperform the return of the MSCI World ESG Leaders (NR) benchmark. The Subfund is actively managed. The benchmark is used as a reference point for portfolio construction and as a basis for setting risk constraints, and/or for Performance Fee measurement purposes. The majority of the Subfund’s equity securities will not necessarily be components of or have weightings derived from the benchmark. The Investment Manager will use its discretion to significantly deviate the weighting of certain components of the benchmark and to significantly invest in companies or sectors not included in the benchmark in order to take advantage of specific investment opportunities. |
Peculiarities |
Current Price * | 145.15 USD | 21.11.2024 |
---|---|---|
Previous Price * | 144.54 USD | 20.11.2024 |
52 Week High * | 162.84 USD | 27.02.2024 |
52 Week Low * | 133.91 USD | 30.11.2023 |
NAV * | 145.15 USD | 21.11.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 1,001,210,494 | |
Unit/Share Assets *** | 24,055,554 | |
Trading Information SIX |
YTD Performance | -6.03% |
29.12.2023 - 21.11.2024
29.12.2023 21.11.2024 |
---|---|---|
YTD Performance (in CHF) | -0.98% |
29.12.2023 - 21.11.2024
29.12.2023 21.11.2024 |
1 month | -2.63% |
21.10.2024 - 21.11.2024
21.10.2024 21.11.2024 |
3 months | -3.54% |
21.08.2024 - 21.11.2024
21.08.2024 21.11.2024 |
6 months | +0.23% |
21.05.2024 - 21.11.2024
21.05.2024 21.11.2024 |
1 year | +9.42% |
21.11.2023 - 21.11.2024
21.11.2023 21.11.2024 |
2 years | -1.64% |
21.11.2022 - 21.11.2024
21.11.2022 21.11.2024 |
3 years | -39.50% |
22.11.2021 - 21.11.2024
22.11.2021 21.11.2024 |
5 years | -0.70% |
21.11.2019 - 21.11.2024
21.11.2019 21.11.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Zai Lab Ltd Ordinary Shares | 4.30% | |
---|---|---|
Zealand Pharma AS | 3.96% | |
Exact Sciences Corp | 3.92% | |
Redcare Pharmacy NV | 3.89% | |
Natera Inc | 3.81% | |
Veeva Systems Inc Class A | 3.75% | |
Inspire Medical Systems Inc | 3.60% | |
Schrodinger Inc Ordinary Shares | 3.51% | |
Doximity Inc Class A | 3.46% | |
Denali Therapeutics Inc | 3.32% | |
Last data update | 31.10.2024 |
TER | 2.55% |
---|---|
TER date | 31.05.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.92% |
Ongoing Charges *** | 2.54% |
SRRI ***
|
|
SRRI date *** | 31.10.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |